Effect of T0901317 on hepatic proinflammatory gene expression in ApoE-/- mice fed a high-fat/high-cholesterol diet

Inflammation

Volumn 30, Issue 3-4, 2007, Pages 105-117

  Dai, Xiaoyan ^a   Ou, Xiang ^a   Hao, Xinrui ^a   Cao, Dongli ^a   Tang, Yaling ^a   Hu, Yanwei ^a   Li, Xiaoxu ^a   Tang, Chaoke ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Atherosclerosis; Inflammation; LXR; Microarray; Nuclear receptors; T0901317

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENTARY DNA; GELATINASE B; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 7; MESSENGER RNA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENIC DIET; CHOLESTEROL DIET; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC ANALYSIS; LIPID DIET; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CHOLESTEROL, DIETARY; DNA-BINDING PROTEINS; GENE EXPRESSION; GENE EXPRESSION PROFILING; INTERLEUKIN-1ALPHA; INTERLEUKIN-6; INTERLEUKIN-7; LIVER; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, MUTANT STRAINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 34250847058     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10753-007-9026-2     Document Type: Article

References (41)

1. Libby, P. 2002. Inflammation in atherosclerosis. Nature 420:868-874.
2. Lusis, A. J. 2000. Atherosclerosis. Nature 407:233-241.
3. Glass, C. K., and J. L. Witztum. 2001. Atherosclerosis: the road ahead. Cell 104:503-516.
4. Zitzer, H., W. Wente, M. B. Brenner, S. Sewing, K. Buschard, J. Gromada, and A. M. Efanov. 2006. Sterol regulatory element-binding protein 1 mediates liver X receptor-beta-induced increases in insulin secretion and insulin messenger ribonucleic acid levels. Endocrinology 147:3898-3905.
5. Tang, C. K., G. H. Yi, J. H. Yang, L. S. Liu, Z. Wang, C. G. Ruan, and Y. Z. Yang. 2004. Oxidized LDL upregulated ATP binding cassette transporter A1 in THP-1 macrophages. Acta Pharmacol. Sin. 25(5):581-586.
6. Joseph, S. B., A. Castrillo, B. A. Laffitte, D. J. Mangelsdorf, and P. Tontonoz. 2003. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9:213-219.
7. Castrillo, A., S. B. Joseph, C. Marathe, D. J. Mangelsdorf, P. Tontonoz. 2003. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J. Biol. Chem. 278:10443-10449.
8. Blaschke, F., Y. Takata, E. Caglayan, A. Collins, P. Tontonoz, W. A. Hsueh, and R. K. Tangirala. 2006. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ. Res. 99:e88-e99.
9. Fowler, A. J., M. Y. Sheu, M. Schmuth, J. Kao, J. W. Fluhr, L. Rhein, J. L. Collins, T. M. Willson, D. J. Mangelsdorf, P. M. Elias, and K. R. Feingold. 2003. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J. Invest. Dermatol. 120:246-255.
10. Terasaka, N., A. Hiroshima, A. Ariga, S. Honzumi, T. Koieyama, T. Inaba, and T. Fujiwara. 2005. Liver X receptor agonists inhibit tissue factor expression in macrophages. Febs J. 272:1546-1556.
11. Peet, D. J., S. D. Turley, W. Ma, B. A. Janowski, J. M. Lobaccaro, R. E. Hammer, and D. J. Mangelsdorf. 1998. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93:693-704.
12. Ratliff, E. P., A. Gutierrez, R. A. Davis. 2006. Transgenic expression of CYP7A1 in LDL receptor-deficient mice blocks diet-induced hypercholesterolemia. J. Lipid. Res. 47:1513-1520.
13. Joseph, S. B., E. McKilligin, L. Pei, M. A. Watson, A. R. Collins, B. A. Laffitte, M. Chen, G. Noh, J. Goodman, G. N. Hagger, J. Tran, T. K. Tippin, X. Wang, A. J. Lusis, W. A. Hsueh, R. E. Law, J. L. Collins, T. M. Willson, and P. Tontonoz. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. U. S. A. 99:7604-7609.
14. Terasaka, N., A. Hiroshima, T. Koieyama, N. Ubukata, Y. Morikawa, D. Nakai, and T. Inaba. 2003. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536:6-11.
15. Lee, C. K., R. Weindruch, and T. A. Prolla. 2000. Gene-expression profile of the ageing brain in mice. Nat. Genet. 25:294-297.
16. Cao, S. X., J. M. Dhahbi, P. L. Mote, and S. R. Spindler. 2001. Genomic profiling of short- and long-term caloric restriction effects in the liver of aging mice. Proc. Natl. Acad. Sci. U. S. A. 98:10630-10635.
17. Levin, N., E. D. Bischoff, C. L. Daige, D. Thomas, C. T. Vu, R. A. Heyman, R. K. Tangirala, and I. G. Schulman. 2005. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25:135-142.
18. Marleau, S., D. Harb, K. Bujold, R. Avallone, K. Iken, Y. Wang, A. Demers, M. G. Sirois, M. Febbraio, R. L. Silverstein, A. Tremblay, and H. Ong. 2005. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. Faseb J. 19:1869-1871.
19. Hansson, G. K., P. Libby, U. Schonbeck, and Z. Q. Yan. 2002. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91:281-291.
20. Libby, P, and Z. S. Galis. 1995. Cytokines regulate genes involved in atherogenesis. Ann. N. Y. Acad. Sci. 748:158-168; discussion 168-170.
21. Libby, P, P. M. Ridker, and A. Maseri. 2002. Inflammation and atherosclerosis. Circulation 105:1135-1143.
22. Recinos, A. 3rd, B. K. Carr, D. B. Bartos, I. Boldogh, J. R. Carmical, L. M. Belalcazar, and A. R. Brasier. 2004. Liver gene expression associated with diet and lesion development in atherosclerosis-prone mice: induction of components of alternative complement pathway. Physiol. Genomics 19:131-142.
23. Martinet, W, D. M. Schrijvers, G. R. De Meyer, J. Thielemans, M. W. Knaapen, A. G. Herman, and M. M. Kockx. 2002. Gene expression profiling of apoptosis-related genes in human atherosclerosis: upregulation of death-associated protein kinase. Arterioscler. Thromb. Vasc. Biol. 22:2023-2029.
24. Tracey, K. J., and A. Cerami. 1994. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45:491-503.
25. Piecyk, M., S. Wax, A. R. Beck, N. Kedersha, M. Gupta, B. Maritim, S. Chen, C. Gueydan, V. Kruys, M. Streuli, and P. Anderson. 2000. TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. Embo J. 19:4154-4163.
26. Dean, J. L., R. Wait, K. R. Mahtani, G. Sully, A. R. Clark, and J. Saklatvala. 2001. The 3′ untranslated region of tumor necrosis factor alpha mRNA is a target of the mRNA-stabilizing factor HuR. Mol. Cell. Biol. 21:721-730.
27. Shurety, W., A. Merino-Trigo, D. Brown, D. A. Hume, and J. L. Stow. 2000. Localization and post-Golgi trafficking of tumor necrosis factor-alpha in macrophages. J. Interferon Cytokine Res. 20:427-438.
28. Landis, M. S., H. V. Patel, and J. P. Capone. 2002. Oxysterol activators of liver X receptor and 9-cis-retinoic acid promote sequential steps in the synthesis and secretion of tumor necrosis factor-alpha from human monocytes. J. Biol. Chem. 277:4713-4721.
29. Galis, Z. S., C. Johnson, D. Godin, R. Magid, J. M. Shipley, R. M. Senior, and E. Ivan. 2002. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ. Res. 91:852-859.
30. Galis, Z. S., G. K. Sukhova, R. Kranzhofer, S. Clark, and P. Libby. 1995. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc. Natl. Acad. Sci. U. S. A. 92:402-406.
31. Pasterkamp, G., A. H. Schoneveld, D. J. Hijnen, D. P. de Kleijn, H. Teepen, A. C. van der Wal, and C. Borst. 2000. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 150:245-253.
32. Kirii, H., T. Niwa, Y. Yamada, H. Wada, K. Saito, Y. Iwakura, M. Asano, H. Moriwaki, and M. Seishima. 2003. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23:656-660.
33. Isoda, K., S. Sawada, N. Ishigami, T. Matsuki, K. Miyazaki, M. Kusuhara, Y. Iwakura, and F. Ohsuzu. 2004. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 24:1068-1073.
34. Blake, G. J., and P. M. Ridker. 2003. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J. Am. Coll. Cardiol. 41:37S-42S.
35. Aggarwal, S., and A. L. Gurney. 2002. IL-17: prototype member of an emerging cytokine family. J. Leukoc. Biol. 71:1-8.
36. Lee, J., W. H. Ho, M. Maruoka, R. T. Corpuz, D. T. Baldwin, J. S. Foster, A. D. Goddard, D. G. Yansura, R. L. Vandlen, W. I. Wood, and A. L. Gurney. 2001. IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J. Biol. Chem. 276:1660-1664.
37. Heinrich, P. C., J. V. Castell, and T. Andus. 1990. Interleukin-6 and the acute phase response. Biochem. J. 265:621-636.
38. Moshage, H. 1997. Cytokines and the hepatic acute phase response. J. Pathol. 181:257-266.
39. Karin, M., and L. Chang. 2001. AP-1-glucocorticoid receptor crosstalk taken to a higher level. J. Endocrinol. 169:447-451.
40. Herrlich, P. 2001. Cross-talk between glucocorticoid receptor and AP-1. Oncogene 20:2465-2475.
41. Nissen, R. M., and K. R. Yamamoto. 2000. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 14:2314-2329.